Agentix 3Q 2026: EPS ($0.00) — 10-Q Summary

Agentix reported no revenue for 3Q 2026, with a net loss of $91.03K, narrower than the prior year's $144.11K loss. Professional fees and R&D expenses decreased, while general and administrative expenses remained unchanged. Diluted EPS was $0.00.

Original reporting
Published Nov 6, 2026, 3:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 3:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Agentix 3Q 2026: EPS ($0.00) — 10-Q Summary — source image
Decision brief

The 30-second read

$AGTXBearishLow
01

Why it matters

The disclosed loss reduction may attract short‑term traders looking for volatility, but the lack of revenue limits upside.

02

Market read

The filing provides fresh, primary data on a small cap's financial health, offering limited trading relevance.

03

What to watch

Potential upcoming contracts or R&D milestones not disclosed in the filing.

Relevance 6/10Novelty 5/10Timing: post‑market filing

Background

Agentix Corp is a micro‑cap listed on a US exchange, reporting quarterly results via a 10‑Q filing.

Company-level read

Ticker impact

$AGTXBearishMedium confidence
Context

Agentix Corp filed its 10‑Q reporting a net loss of $91.03K and zero revenue for Q3 2026, with EPS of $0.00.

Expected impact

likely pressure as the market prices in the continued loss and lack of revenue

Evidence & confidence

Micro‑cap earnings with no revenue and a modest loss reduction provide little catalyst for price appreciation.

Market effects

Signals weakness in the niche professional‑services segment the company operates in.

Limited to US micro‑cap investors; no broader regional effect.

Minimal, as the company is small and not globally significant.

Counterpoint

If the loss narrowing continues, the stock could be a speculative play for a turnaround.

Key entities

  • Agentix Corp

    Micro‑cap firm reporting Q3 2026 results.

Related articles

$RVMDMedAI 8/10

Why is Revolution Medicines stock surging today?

Revolution Medicines (RVMD) stock rose 7% after reporting Q3 revenue of $197.6M, exceeding estimates, driven by its new drug RASONQUE. Analysts raised price targets, with HC Wainwright setting a $350 target. The company has strong cash reserves and reaffirmed its 2026 expense guidance. NASDAQ and S&P 500 gains provided a supportive market backdrop.

HighAI 9/10

Why is Ubiquiti stock surging today?

Ubiquiti's stock rose 16.9% after reporting fiscal Q1 2027 results. Revenue was $1.026 billion, beating estimates, with GAAP EPS of $5.29. The Enterprise Technology segment drove growth. The company declared a $1.00 dividend. Analysts have mixed views, with a consensus price target of $734.50. The broader market also gained.

$DVNHighAI 8/10

Devon Energy 3Q 2026: Revenue $6.86B, EPS $0.88 — 10-Q Summary

Devon Energy reported Q3 2026 revenue of $6.86B, up 58.4% YoY, and net income of $1.01B, up 46.7% YoY. EPS was $0.88, down 19.3% YoY. Production increased to 1,668 MBoe/d. The company repurchased $415M in shares, paid $366M in dividends, and expects $1B in annual synergies by 2027. It also agreed to sell Eagle Ford assets for $4.2B, closing expected in early 2027.

$MCDHighAI 9/10

McDonald’s 3Q 2026: Revenue $7.16B, EPS $3.51 — 10-Q Summary

McDonald's reported 3Q 2026 revenue of $7.16B, up 1.1% YoY, and net income of $2.49B, up 9.1% YoY. Global comparable sales rose 1.5%, while U.S. sales declined 0.2%. The company expects 2,500 restaurant openings for the year. According to the company, higher franchised margins and operating income drove results.